884488-07-7

Usage

Uses

Used in Pharmaceutical Industry:
(1S,3aR,7aR)-1-((S)-1-(3-hydroxy-3-Methylbutoxy)ethyl)-7a-Methylhexahydro-1H-inden-4(2H)-one is used as a potential pharmaceutical compound for its possible biological activity due to the presence of the hydroxybutyl group.
Used in Biologically Active Products:
(1S,3aR,7aR)-1-((S)-1-(3-hydroxy-3-Methylbutoxy)ethyl)-7a-Methylhexahydro-1H-inden-4(2H)-one is used as a component in biologically active products, leveraging its potential biological activity for specific applications.
Note: The specific applications and uses of (1S,3aR,7aR)-1-((S)-1-(3-hydroxy-3-Methylbutoxy)ethyl)-7a-Methylhexahydro-1H-inden-4(2H)-one are not explicitly detailed in the provided materials. The potential uses listed above are inferred based on the compound's structure and the presence of a hydroxybutyl group, which may suggest biological activity. Further research and analysis would be necessary to confirm these uses and explore additional applications.

Upstream product

• 192573-37-8 (20S)-de-A,B-22-oxacholestane-8β,25-diol 
• 64190-52-9 (8S,20S)-de-A,B-20-(hydroxymethyl)pregnan-8-ol 
• 140659-43-4 [1S-(1β,4β,7aβ)]-[1R-(3aα)]-octahydro-1-acetyl-4-[(tert-butyldimethylsilyl)oxy]-7a-methyl-1H-indene 
• 100928-04-9 (S)-2-((1R,3aR,4S,7aR)-4-((tert-butyldimethylsilyl)oxy)-7a-methyloctahydro-1H-inden-1-yl)propyl 4-methylbenzenesulfonate 
• 192573-35-6 3-{(S)-1-[(1S,3aR,4S,7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-1-yl]-ethoxy}-propionic acid ethyl ester 
• 192573-34-5 (E)-3-{(S)-1-[(1S,3aR,4S,7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-1-yl]-ethoxy}-acrylic acid ethyl ester 
• 147725-62-0 (20S)-De-A,B-8β-[(tert-butyldimethylsilyl)oxy]pregnan-20-ol 
• 192573-36-7 4-{[(1S)-1-((1S,3aR,4S,7aR)-4-{[tert-butyl(dimethyl)silyl]oxy}-7a-methyloctahydro-1H-inden-1-yl)ethyl]oxy}-2-methylbutan-2-ol 
• 104651-47-0 (S)-2-[(1R,3aR,4S,7aR)-octahydro-4-[(1,1-dimethylethyl)dimethylsilyloxy]-7a-methyl-1H-inden-1-yl]propanal 
• 66774-80-9 (S)-2-((3R,3aR,7S,7aR)-octahydro-7-hydroxy-3a-methyl-1H-inden-3-yl)propyl 4-methylbenzenesulfonate 
• 17689-66-6 3-hydroxy-3-methylbutyl toluene-4-sulfonate 
• 2568-33-4 3-methyl-butane-1,3-diol 
• 897657-83-9 (20S)-de-A,B-8β,25-bis-[(tert-butyldimethylsilyl)oxy]-22-oxacholestane 
• 681434-22-0 toluene-4-sulfonic acid 3-[(tert-butyldimethylsilyl)oxy]-3-methylbutyl ester 

Relevant academic research and scientific papers

VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING

The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Synthesis and biological activities of new 1α,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain

In a series of studies on structure-activity relationships of 2-substituted 19-norvitamin D analogs, we found that 1α,25-dihydroxy-19-norvitamin D3 analogs with 2β-hydroxyethoxy or 2E-hydroxyethylidene moieties show strong binding affinity for the vitamin D receptor (VDR) as well as marked transcriptional activity. To further examine the effects of side chain structure on the activity of 2-substituted 19-norvitamin D analogs, we have synthesized new 19-norvitamin D3 analogs with modifications in both the A-ring at the C(2) position and the side chain. The side chains of these analogs contained a double bond between C(22) and C(23) or an oxygen atom at C(22). The biological activity of the analogs was evaluated in vitro. All the side chain-modified analogs were less active than 1α,25-dihydroxyvitamin D3 1e and the parent compounds 3-6e possessing a natural 20R-configuration in binding to the VDR, but, except for the (20R)-22-oxa analogs 3-6d, were significantly more potent in transcriptional activity. Of the side-chain-modified analogs 4 and 5, the 2β-hydroxyethoxy- and 2E-hydroxyethylidene-22,24-diene-24a,26a,27a-trihomo analogs showed markedly higher transcriptional activity (25- and 17.5-fold, respectively) compared with 1e. Elongation of the side chain at the C-24, C-26, and C-27 positions and introduction of a 22,24-diene moiety strongly increased transcriptional activity, as seen in the 20-epi analogs 3-6f.

A new approach to the synthesis of the 25-hydroxy-22-oxa-vitamin D3 side chain

An efficient new method is described for the construction of the 25-hydroxy-22-oxavitamin D3 side-chain, which is present in several analogues of calcitriol with antitumour activity.